# Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

> **NCT00498836** · PHASE2 · COMPLETED · sponsor: **Clavis Pharma** · enrollment: 18 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** CP-4055
- **DRUG:** Sorafenib (Nexavar)

## Key facts

- **NCT ID:** NCT00498836
- **Lead sponsor:** Clavis Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2013-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00498836

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00498836, "Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00498836. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*